BILGEN
in vitro anticancer biomolecule screening service aims to identify
novel biologically active molecules that can be considered as candidate
anti-cancer drugs. Our service is operational since the beginning of
2007. Our facility served to many centers in Turkey (Hacettepe
University, Ankara University, Ataturk University) and abroad
(École nationale supérieure de chimie de Paris).
So far
we screened up to 700 synthetic or natural plant originated compounds
for their potential cytotoxic anticancer activity. For this purpose we
made 42000 experiments. In our initial screening procedure we use 3
human tumor cell lines (liver carcinoma Huh7, breast carcinoma T47-D
and colon carcinoma HCT116). After the detection of an activity,
further cell lines are tested. Dose response curve for each compound
can be determined along with IC50 values. Our Screening methodology is
based on NCI-SRB assay (Shoemaker, R. H. The NCI60 Human Tumour Cell
line Anticancer Drug Screen. Nature Reviews, 6: 813-823, 2006.).
In addition our laboratory we developed an established in vitro kinase activity assay for the drug candidates. So far we identified 7 kinase inhibitors. Our preliminary results were presented International meetings (ILCA-2009, ISOPS-9, 42nd IUPAC Congress).
Experimental procedures
In addition our laboratory we developed an established in vitro kinase activity assay for the drug candidates. So far we identified 7 kinase inhibitors. Our preliminary results were presented International meetings (ILCA-2009, ISOPS-9, 42nd IUPAC Congress).
Experimental procedures